19th May 2015 07:54
LONDON (Alliance News) - Life sciences company Abzena PLC on Tuesday said its Antitope Ltd subsidiary has entered a collaboration deal with European biotechnology firm Apitope.
Under the agreement, Antitope will investigate and measure the immunological status of haemophilia A patients after treatment with Apitope's ATX-F8-117 compound.
No financial details were disclosed on the agreement.
"We are excited by the opportunity to be working with Apitope to design and run a bespoke study which will help them understand patient responses to treatment with ATX-F8-117," said Abzena's Chief Scientific Officer Matthew Baker.
Shares in Abzena were untraded Tuesday, having last traded at 81.00 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Abzena